Network officials also said voters should expect more of a Koch focus on grassroots activism throughout the 2020 election cycle.Politicsread more
In a room full of avowed capitalists, policies that sound to some like socialism are bound not to go over well.Delivering Alpharead more
GM's usage of temporary workers, potential closure of plants and health care contributions remain major sticking points, according to people familiar with the talks.Autosread more
Republicans and Democrats have long since separated themselves by ideology, leaving each more uniformly conservative or liberal than ever. And now a new data analysis by the...Politicsread more
A Missouri man died of vaping-related illness, officials announced Thursday.Health and Scienceread more
At least in terms of monetary policy, Pence says should be taking after other regions who keep their benchmark interest rates near zero.Delivering Alpharead more
AT&T isn't focused on selling or divesting DirecTV, despite pressure from stakeholder Elliott Management, sources tell CNBC.Technologyread more
Patrick Shyu, a former tech lead at Google, has posted a series of videos making fun of Facebook, where he worked as a software engineer until last month.Technologyread more
The measure to keep the government running through Nov. 21 now heads to the Senate, where McConnell has signaled he will back a temporary spending plan.Politicsread more
Amazon's purchase comes as part of its plan to convert its delivery fleet to 100% renewable energy by 2030. The e-commerce retailer already runs 40% of its fleet on renewable...Autosread more
As part of the plan, Amazon has agreed to purchase 100,000 electric delivery vans from vehicle manufacturer Rivian.Technologyread more
Illumina shares shed nearly 25 percent Tuesday after the San Diego-based biotech company trimmed its third-quarter revenue estimates.
The shortfall was due to a decline in demand for its high-speed genetic sequencing instruments used to analyze large genomes, the company said.
Illumina now expects to report revenue of about $607 million, which is about 10 percent higher than last year's third-quarter revenue of $550 million. Previously, the company expected to report revenue in the range of $625 million to $630 million.
Based on current trends, the company said it expects its fourth-quarter revenue will be flat to slightly up sequentially.
Shares of Pacific Biosciences of California, another biotechnology company focused on genetic sequencing, dropped 5.8 percent Tuesday morning.
The key biotechnology ETF declined 3.8 percent Tuesday.
Illumina's shares closed at $184.85 on Monday before the the company released the third-quarter revenue forecast.